Degree 【 display / non-display 】

Degree 【 display / non-display 】

• 札幌医科大学   医学博士

Research Areas 【 display / non-display 】

Research Areas 【 display / non-display 】

• Life sciences   Obstetrics and gynecology  

Affiliation 【 display / non-display 】

Affiliation 【 display / non-display 】

• 札幌医科大学   産婦人科   講師  

Research Interests 【 display / non-display 】

Research Interests 【 display / non-display 】

• 婦人科腫瘍

Papers 【 display / non-display 】

Papers 【 display / non-display 】

• Successful Outcome of Stage IB3 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Vaginal Radical Trachelectomy: A Case Report.

  Masato Tamate, Motoki Matsuura, Masayuki Someya, Tasuku Mariya, Shinichi Ishioka, Tsuyoshi Saito

  Cureus   16 ( 10 ) e71626  2024.10  [International journal]

  　View Summary

  Vaginal trachelectomy, which involves resecting the cervix and its parametrium, is a fertility-sparing option for the treatment of early-stage cervical cancer. Although no consensus has been reached on whether simple or radical trachelectomy is preferable, the vaginal approach is typically avoided for tumors larger than 2 cm due to concerns about recurrence. However, some evidence suggests that fertility preservation may still be viable for select patients with larger tumors. This case report describes a woman with bulky cervical cancer who wished to preserve her fertility. After undergoing neoadjuvant chemotherapy (NAC) and vaginal radical trachelectomy (VRT), she achieved a favorable oncological and perinatal outcome, successfully giving birth to a near-full-term baby. The report outlines the patient's management before, during, and after the procedure, including perinatal care. While careful selection of candidates is crucial, accumulating case reports and future trials are expected to shed more light on this treatment approach.

  DOI PubMed

• Human papillomavirus self‐sampling and urine‐sampling tests and the management and short‐term outcomes of cervical intraepithelial neoplasia: A prospective observational study

  Motoki Matsuura, Masato Tamate, Sachiko Nagao, Taishi Akimoto, Fukiko Kasuga, Kimihito Saito, Satoshi Shikanai, Yoko Nishimura, Mizue Teramoto, Tsuyoshi Saito

  Journal of Obstetrics and Gynaecology Research    2024.10

  DOI

• Risk-reducing salpingo-oophorectomy for hereditary breast and ovarian cancer patients with vaginal natural orifice transluminal endoscopic surgery (vNOTES)

  Masato Tamate, Motoki Matsuura, Sachiko Nagao, Shoko Kurokawa, Taishi Akimoto, Tsuyoshi Saito

  International Journal of Gynecologic Cancer    2024.09

  DOI

• Niraparib in Japanese patients with heavily pretreated, homologous recombination-deficient ovarian cancer: final results of a multicenter phase 2 study.

  Daisuke Aoki, Tsutomu Tabata, Satoshi Yanagida, Toshiaki Nakamura, Eiji Kondo, Junzo Hamanishi, Kenichi Harano, Kosei Hasegawa, Takeshi Hirasawa, Kensuke Hori, Shinichi Komiyama, Motoki Matsuura, Hidekatsu Nakai, Hiroko Nakamura, Jun Sakata, Kazuhiro Takehara, Munetaka Takekuma, Yoshihito Yokoyama, Yoichi Kase, Shuuji Sumino, Junpei Soeda, Ai Kato, Ajit Suri, Aikou Okamoto, Toru Sugiyama

  Journal of gynecologic oncology   35 ( 5 ) e114  2024.09  [International journal]

  　View Summary

  OBJECTIVE: To evaluate the long-term efficacy and safety of niraparib in Japanese women with heavily pretreated ovarian cancer. METHODS: This was the follow-up analysis of a phase 2, multicenter, open-label, single-arm study in Japanese women with homologous recombination-deficient, platinum-sensitive, relapsed, high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who had completed 3-4 lines of chemotherapy and were poly(ADP-ribose) polymerase inhibitor naïve. Participants received niraparib (starting dose, 300 mg) once daily in continuous 28-day cycles until objective disease progression, unacceptable toxicity, or consent withdrawal. The primary endpoint was confirmed objective response rate (ORR), as assessed using Response Evaluation Criteria in Solid Tumors version 1.1. Safety evaluations included treatment-emergent adverse events (TEAEs). RESULTS: 20 patients were enrolled in the study and included in both efficacy and safety analyses. Median total study duration was 759.5 days. Median dose intensity was 201.3 mg/day. Confirmed ORR was 60.0% (90% confidence interval [CI]=39.4-78.3); 2 patients had complete response and 10 patients had partial response. Median duration of response was 9.9 months (95% CI=3.9-26.9) and the disease control rate was 90.0% (95% CI=68.3-98.8). The most common TEAEs were anemia (n=15), nausea (n=12), and decreased platelet count (n=11). TEAEs leading to study drug dose reduction, interruption, or discontinuation were reported in 16 (80.0%), 15 (75.0%), and 2 patients (10.0%), respectively. CONCLUSION: The long-term efficacy and safety profile of niraparib was consistent with previous findings in the equivalent population in non-Japanese patients. No new safety signals were identified. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03759600.

  DOI PubMed

• 当院における類内膜癌G3症例の細胞診・病理形態学的評価と臨床経過の検討

  幅田 周太朗, 齋藤 晋平, 有元 千紘, 野藤 五沙, 長尾 沙智子, 黒川 晶子, 玉手 雅人, 真里谷 奨, 秋元 太志, 松浦 基樹, 岩崎 雅宏, 齋藤 豪

  日本婦人科腫瘍学会学術講演会プログラム・抄録集 ( (公社)日本婦人科腫瘍学会 )  66回   327 - 327  2024.07

display all >>

Misc 【 display / non-display 】

Misc 【 display / non-display 】

• LBC検体によるNGSを子宮体癌早期スクリーニングにどう応用するべきか

  松浦基樹, 玉手雅人, 秋元太志, 幅田周太朗, 岩崎雅宏, 畠山晴良, 高根希世子, 山口貴世志, 古川洋一, 齋藤豪

  日本臨床細胞学会雑誌(Web)   62  2023

  J-GLOBAL

• Identification of cancer driver mutations in liquid endometrial biopsy for the screening of endometrial diseases.

  高根希世子, 松浦基樹, 山口貴世志, 池上恒雄, 畠山晴良, 黒川晶子, 玉手雅人, 秋元太志, 岩崎雅宏, 杉田慎太郎, 長谷川匡, 大田泰徳, 齋藤豪, 古川洋一

  日本癌学会学術総会抄録集(Web)   82nd  2023

  J-GLOBAL

• 前治療歴を有する高悪性度漿液性卵巣癌患者を対象としたニラパリブの国内第II相臨床試験の最終結果(The Final Results of a Japanese Phase 2 Study of Niraparib in Heavily Pretreated, HRd High-grade Serous Ovarian Cancer Patients)

  中村 俊昭, 田畑 務, 柳田 聡, 近藤 英司, 濱西 潤三, 原野 謙一, 長谷川 幸清, 平澤 猛, 堀 謙輔, 小宮山 慎一, 松浦 基樹, 中井 英勝, 中村 紘子, 坂田 純, 竹原 和宏, 武隈 宗孝, 横山 良仁, 加瀬 陽一, 杉山 徹, 青木 大輔

  日本婦人科腫瘍学会学術講演会プログラム・抄録集 ( (公社)日本婦人科腫瘍学会 )  64回   193 - 193  2022.07

• プラチナ製剤感受性の日本人再発卵巣癌患者を対象としたニラパリブの第II相臨床試験の最終結果(The Final Results of a Phase 2 Study of Niraparib in Japanese Patients with Platinum-Sensitive Recurrent Ovarian Cancer)

  竹島 信宏, 安岡 稔晃, 濱西 潤三, 長谷川 幸清, 松浦 基樹, 三浦 清徳, 長尾 昌二, 中井 英勝, 田中 尚武, 徳永 英樹, 牛嶋 公生, 渡利 英道, 横山 良仁, 加瀬 陽一, 角野 修司, Suri Ajit, 板持 広明, 竹原 和宏

  日本婦人科腫瘍学会学術講演会プログラム・抄録集 ( (公社)日本婦人科腫瘍学会 )  64回   192 - 192  2022.07

• 子宮内膜症,子宮内膜癌細胞におけるAngulin-1/Lipolysis Stimulated Lipoprotein Receptor(LSR)の役割

  斉藤公仁, 斉藤公仁, 嶋田浩志, 金野匠, 倉ありさ, 倉ありさ, 岡田匡氷, 郷久晴朗, 幸野貴之, 松浦基樹, 齋藤豪, 小島隆

  日本臨床分子形態学会総会・学術集会講演プログラム・要旨集   54th  2022

  J-GLOBAL

display all >>